tucatinib
Start here
On October 8, 2026, the FDA approved atezolizumab (Tecentriq, Genentech) combined with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III mismatch repair-deficient (dMMR) colon cancer in adults and children aged 2 and older. In the same window, the FDA also approved tucatinib maintenance therapy for HER2-positive breast cancer. On the same day, China's CDE released two draft guidances for comment, covering GVHD clinical trials and nonclinical PK studies.
Excerpted from mp.weixin.qq.com
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comFDA Approves Atezolizumab for dMMR Stage III Colon Cancer and Tucatinib for HER2-Positive Breast Cancer
On October 8, 2026, the FDA approved atezolizumab (Tecentriq, Genentech) combined with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III mismatch repair-deficient (dMMR) colon cancer in adults and children aged 2 and older. In the same window, the FDA also approved tucatinib maintenance therapy for HER2-positive breast cancer. On the same day, China's CDE released two draft guidances for comment, covering GVHD clinical trials and nonclinical PK studies.
Heat trend for this story
Heat now 17·Peak in the comparable set 25 (Oct 24 22:00)·Change over 24h in the comparable set +91%·Participants now 4
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.